FENCFennec Pharmaceuticals Inc.
Is the business good?
Margins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is FENC?
Fennec Pharmaceuticals Inc. keeps −1.9% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +32%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 0.36%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −10521% |
| FY2022 | −1472% |
| FY2023 | −60% |
| FY2024 | 5.4% |
| FY2025 | −14% |
Details›
- Operating margin12 months to Q2 2026
- −1.9%
- Net margin12 months to Q2 2026
- −5.5%
- R&D as % of revenue
- 0.36%
- Revenue, trailing twelve months
- $59M
- Net income, trailing twelve months
- −$3.3M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from FENC and who it buys from, as the companies report it.
- Three customers10%
Combined share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; FENC’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.